Marina Mourão

Marina Mourão


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2013 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MMMartin Marek
Martin Marek
SKSrinivasaraghavan Kannan
Srinivasaraghavan Kannan
AHAlexander-Thomas Hauser
Alexander-Thomas Hauser
MMMarina Mourão
Marina Mourão
SCStéphanie Caby
Stéphanie Caby
CRChristophe Romier
Christophe Romier
The treatment of schistosomiasis, a disease caused by blood flukes parasites of the Schistosoma genus, depends on the intensive use of a single drug, praziquantel, which increases the likelihood of the development of drug-resistant parasite strains and renders the search for new drugs a strategic priority. Currently, inhibitors of human epigenetic enzymes are actively investigated as novel anti-cancer drugs and have the potential to be used as new anti-parasitic agents. Here, we report that Schistosoma mansoni histone deacetylase 8 (smHDAC8), the most expressed class I HDAC isotype in this organism, is a functional acetyl-L-lysine deacetylase that plays an important role in parasite infectivity. The crystal structure of smHDAC8 shows that this enzyme adopts a canonical α/β HDAC fold, with specific solvent exposed loops corresponding to insertions in the schistosome HDAC8 sequence. Importantly, structures of smHDAC8 in complex with generic HDAC inhibitors revealed specific structural changes in the smHDAC8 active site that cannot be accommodated by human HDACs. Using a structure-based approach, we identified several small-molecule inhibitors that build on these specificities. These molecules exhibit an inhibitory effect on smHDAC8 but show reduced affinity for human HDACs. Crucially, we show that a newly identified smHDAC8 inhibitor has the capacity to induce apoptosis and mortality in schistosomes. Taken together, our biological and structural findings define the framework for the rational design of small-molecule inhibitors specifically interfering with schistosome epigenetic mechanisms, and further support an anti-parasitic epigenome targeting strategy to treat neglected diseases caused by eukaryotic pathogens. Schistosomiasis, a neglected parasitic disease caused by flatworms of the genus Schistosoma, is responsible for hundreds of thousands of deaths yearly. Its treatment currently depends on a single drug, praziquantel, with reports of drug-resistant parasites. Human epigenetic enzymes, in particular histone deacetylases (HDACs), are predominantly attractive inhibitory targets for anti-cancer therapies. Validated scaffolds against these enzymes could also be used as leads in the search for novel specific drugs against schistosomiasis. In our study, we show that Schistosoma mansoni histone deacetylase 8 (smHDAC8) is a functional acetyl-L-lysine deacetylase that plays an important role in parasite infectivity and is therefore a relevant target for drug discovery. The determination of the atomic structures of smHDAC8 in complex with generic HDAC inhibitors revealed that the architecture of the smHDAC8 active site pocket differed significantly from its human counterparts and provided a framework for the development of inhibitors selectively interfering with schistosome epigenetic mechanisms. In agreement, this information enabled us to identify several small-molecule scaffolds that possess specific inhibitory effects on smHDAC8 and cause mortality in schistosomes. Our results provide the proof of concept that targeting epigenetic enzymes is a valid approach to treat neglected diseases caused by eukaryotic pathogens.

19 June 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LALuiza Freire de Andrade
Luiza Freire de Andrade
MMMarina Mourão
Marina Mourão
JGJuliana Assis Geraldo
Juliana Assis Geraldo
FCFernanda Sales Coelho
Fernanda Sales Coelho
LSLarissa Lopes Silva
Larissa Lopes Silva
GOGuilherme Oliveira
Guilherme Oliveira
Protein kinases are proven targets for drug development with an increasing number of eukaryotic Protein Kinase (ePK) inhibitors now approved as drugs. Mitogen-activated protein kinase (MAPK) family members connect cell-surface receptors to regulatory targets within cells and influence a number of tissue-specific biological activities such as cell proliferation, differentiation and survival. However, the contributions of members of the MAPK pathway to schistosome development and survival are unclear. We employed RNA interference (RNAi) to elucidate the functional roles of five S. mansoni genes (SmCaMK2, SmJNK, SmERK1, SmERK2 and SmRas) involved in MAPK signaling pathway. Mice were injected with post-infective larvae (schistosomula) subsequent to RNAi and the development of adult worms observed. The data demonstrate that SmJNK participates in parasite maturation and survival of the parasites, whereas SmERK are involved in egg production as infected mice had significantly lower egg burdens with female worms presenting underdeveloped ovaries. Furthermore, it was shown that the c-fos transcription factor was overexpressed in parasites submitted to RNAi of SmERK1, SmJNK and SmCaMK2 indicating its putative involvement in gene regulation in this parasite's MAPK signaling cascade. We conclude that MAPKs proteins play important roles in the parasite in vivo survival, being essential for normal development and successful survival and reproduction of the schistosome parasite. Moreover SmERK and SmJNK are potential targets for drug development. Enzymes known as mitogen-activated protein kinases (MAP kinases/MAPKs) influence a number of essential biological activities, such as cell proliferation, differentiation and survival. However, for the Schistosoma mansoni flatworm parasite, very little is known about these enzymes. We used RNA interference (RNAi), a technique designed to decrease or stop the production of specific proteins of interest, to examine the contributions of five Schistosoma mansoni MAPKs to parasite growth and survival. After inducing the RNAi effect in young parasites, we then transferred the worms into mice and after 37 days, counted the number of surviving adult worms in the bloodstream, eggs in the liver, and examined those surviving worms for morphological defects. We found that RNAi of SmJNK decreases parasite survival by 56%, whereas RNAi of SmERK slows the maturation of the ovary and, thus, egg-laying. We also noted that c-fos, that is responsible for activating genes in the genome, was upregulated after RNAi of MAPKs. Our results help define the importance of MAPKs in the normal development and survival of the schistosome parasite and suggest one or more of these enzymes may be useful as drug targets to treat schistosomiasis.

11 August 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MMMarina Mourão
Marina Mourão
NDNathalie Dinguirard
Nathalie Dinguirard
GFGlória R. Franco
Glória R. Franco
TYTimothy P. Yoshino
Timothy P. Yoshino
RNA interference (RNAi) represents the only method currently available for manipulating gene-specific expression in Schistosoma spp., although application of this technology as a functional genomic profiling tool has yet to be explored. In the present study 32 genes, including antioxidants, transcription factors, cell signaling molecules and metabolic enzymes, were selected to determine if gene knockdown by RNAi was associated with morphologically definable phenotypic changes in early intramolluscan larval development. Transcript selection was based on their high expression in in vitro cultured S. mansoni primary sporocysts and/or their potential involvement in developmental processes. Miracidia were allowed to transform to sporocysts in the presence of synthesized double-stranded RNAs (dsRNAs) and cultivated for 7 days, during which time developing larvae were closely observed for phenotypic changes including failure/delay in transformation, loss of motility, altered growth and death. Of the phenotypes evaluated, only one was consistently detected; namely a reduction in sporocyst size based on length measurements. The size-reducing phenotype was observed in 11 of the 33 (33%) dsRNA treatment groups, and of these 11 phenotype-associated genes (superoxide dismutase, Smad1, RHO2, Smad2, Cav2A, ring box, GST26, calcineurin B, Smad4, lactate dehydrogenase and EF1α), only 6 demonstrated a significant and consistent knockdown of specific transcript expression. Unexpectedly one phenotype-linked gene, superoxide dismutase (SOD), was highly induced (∼1600-fold) upon dsRNA exposure. Variation in dsRNA-mediated silencing effects also was evident in the group of sporocysts that lacked any definable phenotype. Out of 22 nonphenotype-expressing dsRNA treatments (myosin, PKCB, HEXBP, calcium channel, Sma2, RHO1, PKC receptor, DHHC, PepcK, calreticulin, calpain, Smeg, 14.3.3, K5, SPO1, SmZF1, fibrillarin, GST28, GPx, TPx1, TPx2 and TPx2/TPx1), 12 were assessed for the transcript levels. Of those, 6 genes exhibited consistent reductions in steady-state transcript levels, while expression level for the rest remained unchanged. Results demonstrate that the efficacy of dsRNA-treatment in producing consistent phenotypic changes and/or altered gene expression levels in S. mansoni sporocysts is highly dependent on the selected gene (or the specific dsRNA sequence used) and the timing of evaluation after treatment. Although RNAi holds great promise as a functional genomics tool for larval schistosomes, our finding of potential off-target or nonspecific effects of some dsRNA treatments and variable efficiencies in specific gene knockdown indicate a critical need for gene-specific testing and optimization as an essential part of experimental design, execution and data interpretation. RNA interference (RNAi) represents the only method currently available for manipulating gene-specific expression in human blood flukes, Schistosoma spp., although its application as a functional genomics tool in early intramolluscan larval stages has been limited to single gene analyses. Accelerating gene discovery efforts over the past 10 years have resulted in extensive, ever-increasing databases of genomic, transcriptomic and EST sequences. Unfortunately, our understanding of the function of the vast majority of these genes has not kept pace with their discovery, and this represents a significant barrier and the next real challenge for investigators of schistosomes, and other parasitic helminths. In the present study, we selected an array of 32 genes expressed in S. mansoni sporocysts to evaluate their susceptibility to double-stranded (ds)RNA treatment and to begin characterizing morphological phenotypes associated with a potential RNAi effect. Results demonstrate that gene knockdown and/or resulting phenotypes are highly transcript-dependent (specific dsRNA sequence used) and vary with time post-dsRNA exposure. Because of this potential variability in both transcript and phenotype expression in response to dsRNA treatment, our findings illustrate that, although a RNAi-type approach holds great promise as a functional reverse-genetics tool for larval schistosomes, its application requires caution in the design and execution of experiments and interpretation of results.

17 November 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MMMarina Mourão
Marina Mourão
NDNathalie Dinguirard
Nathalie Dinguirard
GFGlória R. Franco
Glória R. Franco
TYTimothy P. Yoshino
Timothy P. Yoshino
Antioxidants produced by the parasite Schistosoma mansoni are believed to be involved in the maintenance of cellular redox balance, thus contributing to larval survival in their intermediate snail host, Biomphalaria glabrata. Here, we focused on specific antioxidant enzymes, including glutathione-S-transferases 26 and 28 (GST26 and 28), glutathione peroxidase (GPx), peroxiredoxin 1 and 2 (Prx1 and 2) and Cu/Zn superoxide dismutase (SOD), known to be involved in cellular redox reactions, in an attempt to evaluate their endogenous antioxidant function in the early-developing primary sporocyst stage of S. mansoni. Previously we demonstrated a specific and consistent RNA interference (RNAi)-mediated knockdown of GST26 and 28, Prx1 and 2, and GPx transcripts, and an unexpected elevation of SOD transcripts in sporocysts treated with gene-specific double-stranded (ds)RNA. In the present followup study, in vitro transforming sporocysts were exposed to dsRNAs for GST26 and 28, combined Prx1/2, GPx, SOD or green-fluorescent protein (GFP, control) for 7 days in culture, followed by assessment of the effects of specific dsRNA treatments on protein levels using semi-quantitative Western blot analysis (GST26, Prx1/2 only), and larval susceptibility to exogenous oxidative stress in in vitro killing assays. Significant decreases (80% and 50%) in immunoreactive GST26 and Prx1/2, respectively, were observed in sporocysts treated with specific dsRNA, compared to control larvae treated with GFP dsRNA. Sporocysts cultured with dsRNAs for GST26, GST28, Prx1/2 and GPx, but not SOD dsRNA, were significantly increased in their susceptibility to H2O2 oxidative stress (60–80% mortalities at 48 hr) compared to GFP dsRNA controls (∼18% mortality). H2O2-mediated killing was abrogated by bovine catalase, further supporting a protective role for endogenous sporocyst antioxidants. Finally, in vitro killing of S. mansoni sporocysts by hemocytes of susceptible NMRI B. glabrata snails was increased in larvae treated with Prx1/2, GST26 and GST28 dsRNA, compared to those treated with GFP or SOD dsRNAs. Results of these experiments strongly support the hypothesis that endogenous expression and regulation of larval antioxidant enzymes serve a direct role in protection against external oxidative stress, including immune-mediated cytotoxic reactions. Moreover, these findings illustrate the efficacy of a RNAi-type approach in investigating gene function in larval schistosomes. Species of the human blood fluke Schistosoma are estimated to infect approximately 200 million people worldwide, resulting in loss of health, vitality and productivity mainly among the world's poorest inhabitants. Since snail intermediate hosts represent an essential part of the flukes' life cycle, an understanding of the strategies used by the intramolluscan schistosome larvae to survive within this host may provide novel approaches for disrupting larval development and thus transmission to humans. Anti-oxidant enzymes produced by the parasite Schistosoma mansoni are believed to play a critical role in the maintenance of cellular redox balance, contributing to larval survival in their snail host, Biomphalaria glabrata. In this study, we have incorporated a RNA interference approach attempting to knock down specific anti-oxidant enzymes, including gluthatione-S-transferases 26 and 28 (GST26 and 28), gluthatione peroxidase (GPx), peroxiredoxins 1 and 2 (Prx1/2) and superoxide dismutase (SOD), and to evaluate their endogenous anti-oxidant function in the sporocyst stage of S. mansoni. Results clearly demonstrated a significantly higher susceptibility of antioxidant double-stranded (ds)RNA-treated larvae to in vitro H2O2 treatment or hemocytic encapsulation compared to GFP dsRNA controls. Taken together, our findings support the hypothesis that endogenous expression and regulation of larval antioxidant enzymes serve a direct role in protection against external oxidative stress, including immune-mediated cytotoxic reactions.

24 January 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LALívia das Graças Amaral Avelar
Lívia das Graças Amaral Avelar
Sandra GavaSandra Gava
Sandra Gava
RNRenata Heisler Neves
Renata Heisler Neves
MSMercedes Carolina Soares Silva
Mercedes Carolina Soares Silva
NANeusa Araújo
Neusa Araújo
MMMarina Mourão
Marina Mourão
Eukaryotic protein kinases (ePKs) are good medical targets for drug development in different biological systems. ePKs participate in many cellular processes, including the p38 MAPK regulation of homeostasis upon oxidative stress. We propose to assess the role of Smp38 MAPK signaling pathway in Schistosoma mansoni development and protection against oxidative stress, parasite survival, and also to elucidate which target genes have their expression regulated by Smp38 MAPK. After a significant reduction of up to 84% in the transcription level by Smp38 MAPK gene knockdown, no visible phenotypic changes were reported in schistosomula in culture. The development of adult worms was tested in vivo in mice infected with the Smp38 knocked-down schistosomula. It was observed that Smp38 MAPK has an essential role in the transformation and survival of the parasites as a low number of adult worms was recovered. Smp38 knockdown also resulted in decreased egg production, damaged adult worm tegument, and underdeveloped ovaries in females. Furthermore, only ~13% of the eggs produced developed into mature eggs. Our results suggest that inhibition of the Smp38 MAPK activity interfere in parasites protection against reactive oxygen species. Smp38 knockdown in adult worms resulted in 80% reduction in transcription levels on the 10th day, with consequent reduction of 94.4% in oviposition in vitro. In order to search for Smp38 MAPK pathway regulated genes, we used an RNASeq approach and identified 1,154 DEGs in Smp38 knockdown schistosomula. A substantial proportion of DEGs encode proteins with unknown function. The results indicate that Smp38 regulates essential signaling pathways for the establishment of parasite homeostasis, including genes related to antioxidant defense, structural composition of ribosomes, spliceosomes, cytoskeleton, as well as, purine and pyrimidine metabolism pathways. Our data show that the Smp38 MAPK signaling pathway is a critical route for parasite development and may present attractive therapeutic targets for the treatment and control of schistosomiasis.

1 March 2018 in Trends in Parasitology
Verified
Journal Article
Closed access
Nikola PalevichNikola Palevich
Nikola Palevich
CBCollette Britton
Collette Britton
LKLaura Kamenetzky
Laura Kamenetzky
MMMakedonka Mitreva
Makedonka Mitreva
MMMarina Mourão
Marina Mourão
BSBarton E. Slatko
Barton E. Slatko